Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses in Spanish overall survival data on afatinib vs gefitinib in patients with EGFR mutation–positive non–small cell lung cancer. (Abstract LBA43)
Alain Ravaud, MD, PhD, of Bordeaux University Hospital, discusses in French phase III findings on sunitinib vs placebo as adjuvant treatment for high-risk renal cell carcinoma after nephrectomy. (Abstract LBA11)
Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses in German study findings on neoadjuvant ipilimumab plus nivolumab in patients with palpable stage III melanoma. (Abstract LBA39)
Tony Mok, MD, of The Chinese University of Hong Kong, discusses the final overall survival analysis from this trial on gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive non-small cell lung cancer after progression on first-line gefitinib. (Abstr 1201O)
Susana N. Banerjee, PhD, MBBS, of The Royal Marsden NHS Foundation Trust, discusses phase II findings on abiraterone in patients with recurrent epithelial ovarian cancer. (Abstract LBA33)
Katja Weisel, MD, of the University of Tübingen, discusses study findings on daratumumab, bortezomib, and dexamethasone vs bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. (Abstract 906O)
